Glympse Bio Revenue and Competitors

Boston, MA USA



Total Funding

Estimated Revenue & Valuation

  • Glympse Bio's estimated annual revenue is currently $2.8M per year.(i)
  • Glympse Bio's estimated revenue per employee is $125,500
  • Glympse Bio's total funding is $96M.

Employee Data

  • Glympse Bio has 22 Employees.(i)
  • Glympse Bio grew their employee count by -4% last year.

Glympse Bio's People

Co-FounderReveal Email/Phone
Chief Scientific OfficerReveal Email/Phone
Chief Financial OfficerReveal Email/Phone
Senior Director, Human ResourcesReveal Email/Phone
Associate Project ManagerReveal Email/Phone
Principal Data ScientistReveal Email/Phone
Scientist II, Synthesis & DiscoveryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Glympse Bio?

We are pioneering the development of synthetic biomarkers ᅢᄁ¬ツᆲ¬タワ biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence ᅢᄁ¬ツᆲ¬タワ that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment. Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases ᅢᄁ¬ツᆲ¬タワ a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human bodyᅢᄁ¬ツᆲ¬トᄁs own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. Itᅢᄁ¬ツᆲ¬トᄁs the new frontier of liquid biopsy. Our lead indication is in NASH, and our second indication is in Oncology. Our development pipeline is broad, and we have preclinical validation in over 10 diseases.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Glympse Bio News

2022-04-13 - Satellite Bio launches with $110M to develop injectable tissues

Satellite Bio lifts off with $110M to fuel development of its implantable ... RELATED: Glympse Bio premieres with $22M series A and plan for...

2020-07-24 - Glympse Bio Raises $46.7M in Series B Financing

Glympse Bio, a Cambridge, Mass.-based biotechnology company, closed a $46.7m Series B financing. The round was led by Section 32 and includes new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, as well as existing investors, includin ...

2020-07-15 - Glympse Bio Raises $46.7M In Series B

Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse's novel biosensor platform in fibrotic dise ...

2020-07-15 - GILEAD SCIENCES, INC. Glympse Bio Raises $46.7 Million in Series B Funding Round

By Colin Kellaher Biotechnology startup Glympse Bio Wednesday said it raised $46.7 million in an oversubscribed Series B financing at an undisclosed valuation. Glympse said Bill Maris' Section 32 venture-capital firm led the round, which also included participation from new investors Temasek, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding